202 related articles for article (PubMed ID: 23086433)
21. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089
[TBL] [Abstract][Full Text] [Related]
22. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.
Butowski N; Colman H; De Groot JF; Omuro AM; Nayak L; Wen PY; Cloughesy TF; Marimuthu A; Haidar S; Perry A; Huse J; Phillips J; West BL; Nolop KB; Hsu HH; Ligon KL; Molinaro AM; Prados M
Neuro Oncol; 2016 Apr; 18(4):557-64. PubMed ID: 26449250
[TBL] [Abstract][Full Text] [Related]
23. Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab.
Pope WB; Xia Q; Paton VE; Das A; Hambleton J; Kim HJ; Huo J; Brown MS; Goldin J; Cloughesy T
Neurology; 2011 Feb; 76(5):432-7. PubMed ID: 21282590
[TBL] [Abstract][Full Text] [Related]
24. Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study.
Morisse MC; Etienne-Selloum N; Bello-Roufai D; Blonski M; Taillandier L; Lorgis V; Noël G; Ahle G; Durán-Peña A; Boone M; Chauffert B
J Neurooncol; 2019 Sep; 144(2):419-426. PubMed ID: 31325146
[TBL] [Abstract][Full Text] [Related]
25. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
26. Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab.
Hilario A; Sepulveda JM; Hernandez-Lain A; Salvador E; Koren L; Manneh R; Ruano Y; Perez-Nuñez A; Lagares A; Ramos A
Clin Transl Oncol; 2017 Jan; 19(1):51-57. PubMed ID: 27026567
[TBL] [Abstract][Full Text] [Related]
27. Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical study.
Brenner A; Zuniga R; Sun JD; Floyd J; Hart CP; Kroll S; Fichtel L; Cavazos D; Caflisch L; Gruslova A; Huang S; Liu Y; Lodi A; Tiziani S
Neuro Oncol; 2018 Aug; 20(9):1231-1239. PubMed ID: 29415215
[TBL] [Abstract][Full Text] [Related]
28. Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma.
Nagpal S; Recht CK; Bertrand S; Thomas RP; Ajlan A; Pena J; Gershon M; Coffey G; Kunz PL; Li G; Recht LD
J Neurooncol; 2015 Jun; 123(2):277-82. PubMed ID: 25935109
[TBL] [Abstract][Full Text] [Related]
29. Role for cytotoxic chemotherapy in patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series.
Chamberlain MC
Expert Rev Neurother; 2012 Aug; 12(8):929-36. PubMed ID: 23002937
[TBL] [Abstract][Full Text] [Related]
30. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
Grivas PD; Daignault S; Tagawa ST; Nanus DM; Stadler WM; Dreicer R; Kohli M; Petrylak DP; Vaughn DJ; Bylow KA; Wong SG; Sottnik JL; Keller ET; Al-Hawary M; Smith DC; Hussain M
Cancer; 2014 Mar; 120(5):692-701. PubMed ID: 24249435
[TBL] [Abstract][Full Text] [Related]
31. Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment.
Ezaki T; Tanaka T; Tamura R; Ohara K; Yamamoto Y; Takei J; Morimoto Y; Imai R; Kuranai Y; Akasaki Y; Toda M; Murayama Y; Miyake K; Sasaki H
Brain Tumor Pathol; 2024 Apr; 41(2):61-72. PubMed ID: 38619734
[TBL] [Abstract][Full Text] [Related]
32. Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572.
Schiff D; Jaeckle KA; Anderson SK; Galanis E; Giannini C; Buckner JC; Stella P; Flynn PJ; Erickson BJ; Schwerkoske JF; Kaluza V; Twohy E; Dancey J; Wright J; Sarkaria JN
Cancer; 2018 Apr; 124(7):1455-1463. PubMed ID: 29313954
[TBL] [Abstract][Full Text] [Related]
33. Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme.
Muhic A; Poulsen HS; Sorensen M; Grunnet K; Lassen U
J Neurooncol; 2013 Jan; 111(2):205-12. PubMed ID: 23184145
[TBL] [Abstract][Full Text] [Related]
34. Outcome of discontinuing bevacizumab prior to malignant glioma progression.
Sherman WJ; Raizer JJ; Grimm SA
J Neurooncol; 2013 Jan; 111(1):87-9. PubMed ID: 23065093
[No Abstract] [Full Text] [Related]
35. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
[TBL] [Abstract][Full Text] [Related]
36. Bevacizumab for Patients with Recurrent Multifocal Glioblastomas.
Burger MC; Breuer S; Cieplik HC; Harter PN; Franz K; Bähr O; Steinbach JP
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29156610
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma.
Kaley TJ; Panageas KS; Mellinghoff IK; Nolan C; Gavrilovic IT; DeAngelis LM; Abrey LE; Holland EC; Lassman AB
J Neurooncol; 2019 Sep; 144(2):403-407. PubMed ID: 31325145
[TBL] [Abstract][Full Text] [Related]
38. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme.
Ballman KV; Buckner JC; Brown PD; Giannini C; Flynn PJ; LaPlant BR; Jaeckle KA
Neuro Oncol; 2007 Jan; 9(1):29-38. PubMed ID: 17108063
[TBL] [Abstract][Full Text] [Related]
39. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Taal W; Oosterkamp HM; Walenkamp AM; Dubbink HJ; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; Boerman D; de Vos FY; Dinjens WN; Enting RH; Taphoorn MJ; van den Berkmortel FW; Jansen RL; Brandsma D; Bromberg JE; van Heuvel I; Vernhout RM; van der Holt B; van den Bent MJ
Lancet Oncol; 2014 Aug; 15(9):943-53. PubMed ID: 25035291
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
Saltz LB; Rosen LS; Marshall JL; Belt RJ; Hurwitz HI; Eckhardt SG; Bergsland EK; Haller DG; Lockhart AC; Rocha Lima CM; Huang X; DePrimo SE; Chow-Maneval E; Chao RC; Lenz HJ
J Clin Oncol; 2007 Oct; 25(30):4793-9. PubMed ID: 17947727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
